⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of ProMIS Neurosciences and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
ProMIS Neurosciences
↗Toronto, Canada / Cambridge, USA
ProMIS Neurosciences is a clinical-stage biotechnology company dedicated to the discovery and development of antibody therapeutics that selectively target toxic misfolded proteins. The company leverages its proprietary target discovery engine, EpiSelect™, to identify Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins, which are considered root causes of various neurodegenerative conditions.
The company's primary focus includes Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), and other related disorders. By designing antibodies that specifically bind to toxic oligomers while sparing normal protein function, ProMIS aims to develop safer and more effective treatments with a reduced risk of side effects such as Amyloid-Related Imaging Abnormalities (ARIA).
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Revenue:$0M
Founded:2015
Ownership:public
Status:operating
FUNDING
Stage:Public
Investors:Affinity Asset Advisors, Ally Bridge Group, Sphera Healthcare
STOCK
Exchange:NASDAQ
Ticker:PMN
PIPELINE
Stage:Phase 1
Lead Drug Stage:Phase 1b
Modalities:Monoclonal Antibody, Vaccines
Active Trials:1
Trial Phases:Phase 1: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:BC Neuroimmunology (diagnostic assays)
COMPETITION
Position:Emerging
Competitors:Biogen, Eli Lilly, Roche, Voyager Therapeutics
LEADERSHIP
Key Executives:
Neil Warma - CEO
Neil Cashman - CSO
Scientific Founders:Neil Cashman
LINKS
Website:promisneurosciences.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with ProMIS Neurosciences. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.